The application describes neutralizing chimeric and humanized anti-human IL- 9 antibodies, and the use thereof to identify neutralizing epitopes on human I L- 9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particular ly disclosed are recombinant antibodies derived from three murine anti-human IL -9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.
RECOMBINANT ANTI-INTERLEUKIN-9 ANTIBODIES